Diabetes Mellitus, Type 2REDEEM-PilotNCT02891382
Feasibility Study on the Impact of Economic Incentives to Improve the Management of Type 2 Diabetes Mellitus
A study testing Diabetes education, Goal setting and Companion Support in people with Diabetes Mellitus, Type 2, run by Universidad Peruana Cayetano Heredia at 1 site in Peru.
Trial summary
This feasibility study aims to compare the implementation process of three different interventions that use economic incentives to promote lifestyle behavioral changes in patients with type 2 diabetes mellitus, and to identify barriers and facilitators linked to the process of implementing each of the interventions. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Diabetes Mellitus, Type 2
- What is being tested?
- Diabetes education, Goal setting and Companion Support
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 54 participants
- Where
- 1 sitePeru
- Study dates
- Jul 2016to Feb 2017
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Type 2 diabetes mellitus
- Body mass index 25-39.9 kg/m2, irrespective of HbA1c status
- Able to give consent
- Available and committed to supporting the participant in achieving their goals
- Able to provide consent
Who cannot join
- Diagnosis of cancer or another serious comorbidity
- Pharmacotherapy for weight loss or corticosteroids
- Pregnant women
- Blindness, amputation, foot ulcer or being on dialysis
- Be companion/team support for another participant in the trial
- Physical or mental condition that does not allow him to help the participant to achieve goals
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Feasibility Study on the Impact of Economic Incentives for Weight Loss to Improve the Management of Type 2 Diabetes Mellitus: REDEEM Feasibility Study
This feasibility study aims to compare the implementation process of three different interventions that use economic incentives to promote lifestyle behavioral changes in patients with type 2 diabetes mellitus, and to identify barriers and facilitators linked to the process of implementing each of the interventions. The interventions are based on economic incentives directed to the patient (individual incentives) or a team comprised by the patient and a partner (mixed incentives).
Design: Three-month randomized control feasibility study to test the feasibility of implementing three types of intervention with economic incentives in patients with diabetes mellitus.
Setting: Diabetes outpatient clinics from a public hospital in Peru.
Read the detailed description
Economic incentives have been used to promote changes in habits such as smoking and weight loss. However, no studies have been done to determine the impact of this strategy on the management of type 2 diabetes mellitus (T2DM). Additionally, previous studies do not describe ways to determine the amount of an economic incentive to promote behavioral changes, e.g adherence to treatment, increased physical activity and adherence to a healthy diet. There are also questions regarding the frequency of incentives, the type of incentive (cash or other prizes), and the preferred payment method that this study will allow us to explore. Furthermore, we want to test whether a "team work approach" (mixed incentives) vs. an "individual approach" (individual incentives) can also play a role in introducing behavioral changes.
The goal of the study is to learn about the implementation process of three different interventions that use economic incentives to promote behavioral changes in patients with T2DM, and identify main barriers and facilitators tied to the implementation process of each intervention.
This feasibility study will provide key insights to inform a future larger study; specifically, we will
- Learn about the experience of participants with T2DM with economic incentives.
- Learn about the experience of the companion/team support partners of the participants with T2DM.
- Evaluate the patient's receptiveness to and comprehension of the educational materials used to promote behavioral changes.
- Evaluate the patient and the companion/team support partner's receptiveness towards the received economic incentive as a tool for promoting behavioral changes.
- Explore the companion/team support partner's activities that are most effective in helping with T2DM management of patients.
- Explore whether patients with T2DM are able to keep a daily record of their efforts to manage their diabetes.
- Evaluate the feasibility of packaging and implementing a future clinical trial that evaluates the impact of the use of economic incentives and teamwork in people with T2DM.
From a clinical perspective, we will evaluate the feasibility of reaching the proposed clinical goals in terms of weight loss and HbA1c levels after the intervention period.
Interventions
Diabetes education (all arms). In the introductory meeting, a diabetes educator will explain to the participants all the procedures, including details of the number of sessions, and the participant's received a manual with information about diabetes management with a tailored weight loss plan. Each participant will be offered up to seven follow- up sessions with the diabetes educator, every two weeks, plus a final session, thus totaling up to 9 one-to-one interactions during the trial, provided that the participant attended all of their meetings. Participants will also be provided with a logbook to register their efforts regarding introducing changes in diet and physical activity. The information from this logbook will provide the starting point for conversations with the diabetes educator during the follow-up sessions, every two weeks.
Goal setting (all arms). To determine eligibility for a cash reward, three goals were pre-specified: (1) Weight loss, 80 PEN if the participant loses one kilogram over a period of two weeks, (2) HbA1c level, 200 PEN if the participant achieves, at the end of the study, a decrease in 1% compared to their baseline level, and (3) HbA1c level and control, 400 PEN if the participant achieves, at the end of the study, a decrease ≥1% of A1c or reaches levels of A1c ≤6.5% compared to their baseline level. At the end of the study, targets for weight loss and HbA1c were evaluated independently, i.e. participants could receive more than one reward provided that each independent target was achieved.
Companion/team support (Arm 2 and Arm 3). A companion/team support for each participant also receives information about diabetes care in the initial session and a brochure to guide and support the treatment process of the participant. The activities of the companion/team support member will be recorded, and they will be offered to join the follow- up sessions with the patient, every two weeks, but these will not be compulsory.
Cash rewards. Two types of rewards will be considered. (1) Individual rewards (Arm 1 and Arm 2), the reward will be provided to the participant. If the participant were to have a companion/team support partner, the cash reward was given to the participant and no rules about sharing the reward (or not) with their companion/team support are established. (2) Shared rewards (Arm 3), i.e. the participant and their companion/team support will receive 50% of the cash reward each.
- Conditions
- Diabetes Mellitus, Type 2
- Being tested
- Diabetes education, Goal setting, Companion Support, Individual Reward, Shared Reward
- Keywords
- Diabetes Mellitus, Type 2, Weight Loss, Financial Incentives, Hemoglobin A, Glycosylated
- Medical subject headings
- Diabetes Mellitus, Type 2, Weight Loss
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Diabetes educationBehavioural
Participants interact with a diabetes educator (DE), every two weeks.
Goal settingBehavioural
Goals for weight loss and change in levels of HbA1c
Companion SupportBehavioural
Patient has a companion/team support partner to support achieving goals.
Individual RewardBehavioural
The cash reward is given to the patient with diabetes.
Shared RewardBehavioural
Patients with diabetes and their companion support will each receive 50% of the cash reward.
| Study group | Role | What they receive |
|---|---|---|
| Individual incentives - Arm 1 | Experimental | This arm receives diabetes education + goal setting + individual rewards Receives: Behavioral: Diabetes education; Behavioral: Goal setting; Behavioral: Individual Reward |
| Mixed incentives (Altruism) - Arm 2 | Experimental | This arm receives diabetes education + goal setting + companion support + individual rewards Receives: Behavioral: Diabetes education; Behavioral: Goal setting; Behavioral: Companion Support; Behavioral: Individual Reward |
| Mixed Incentives (Cooperation) - Arm 3 | Experimental | This arm receives diabetes education + goal setting + companion support + shared rewards Receives: Behavioral: Diabetes education; Behavioral: Goal setting; Behavioral: Companion Support; Behavioral: Shared Reward |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Glycated Hemoglobin
HbA1c change at 3 months from baseline
Measured: Baseline and 3 months
Secondary outcomes (1)
Change in Weight
Weight change at 3 months from baseline
Measured: Baseline and 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Sep 2016 (estimated)
- Study startJul 2016
- Primary completionFeb 2017
- Study completionFeb 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Diabetes Mellitus, Type 2Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 54 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidad Peruana Cayetano Heredia
- Sponsor type
- University, hospital or other
- Collaborators
- Johns Hopkins Bloomberg School of Public Health
- Responsible party
- Sponsor
- Investigators
- Jaime Miranda, MD, PhD, Principal investigator, Universidad Peruana Cayetano HerediaAntonio Trujillo, PhD, Principal investigator, Johns Hopkins Bloomberg School of Public Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02891382
- Sponsor's protocol ID
- MR/M007405/1
- Acronym
- REDEEM-Pilot
- Status last verified
- Jan 2022
- First submitted
- 31 Aug 2016
- Last updated
- 2 Feb 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- Individual data sharing
- Yes: Following on MRC's data sharing policy, we plan to make our quantitative datasets available in platforms for data sharing (e.g. Figshare, etc.). Qualitative data will be available upon request.
Publications
Pesantes MA, Del Valle A, Diez-Canseco F, Bernabe-Ortiz A, Portocarrero J, Trujillo A, Cornejo P, Manrique K, Miranda JJ. Family Support and Diabetes: Patient's Experiences From a Public Hospital in Peru. Qual Health Res. 2018 Oct;28(12):1871-1882. doi: 10.1177/1049732318784906. Epub 2018 Aug 1.
PubMed 30066604Miranda JJ, Lazo-Porras M, Bernabe-Ortiz A, Pesantes MA, Diez-Canseco F, Cornejo SDP, Trujillo AJ. The effect of individual and mixed rewards on diabetes management: A feasibility randomized controlled trial. Wellcome Open Res. 2019 Feb 5;3:139. doi: 10.12688/wellcomeopenres.14824.3. eCollection 2018.
PubMed 30662958
Study at a glance
From the registry record, last updated by the sponsor on 2 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility Study on the Impact of Economic Incentives for Weight Loss to Improve the Management of Type 2 Diabetes Mellitus: REDEEM Feasibility Study
- ClinicalTrials.gov ID
- NCT02891382
- Acronym / sponsor ID
- REDEEM-Pilot / MR/M007405/1
- Conditions
- Diabetes Mellitus, Type 2
- Keywords
- Diabetes Mellitus, Type 2, Weight Loss, Financial Incentives, Hemoglobin A, Glycosylated
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 54 participants (actual)
- Lead sponsor
- Universidad Peruana Cayetano HerediaUniversity, hospital or other
- Collaborators
- Johns Hopkins Bloomberg School of Public Health
- Study start
- Jul 2016
- Primary completion
- Feb 2017 (actual)
- Study completion
- Feb 2017 (actual)
- First posted
- 7 Sep 2016 (estimated)
- Results
- Posted 2 Feb 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This feasibility study aims to compare the implementation process of three different interventions that use economic incentives to promote lifestyle behavioral changes in patients with type 2 diabetes mellitus, and to identify barriers and facilitators linked to the process of implementing each of the interventions. The interventions are based on economic incentives directed to the patient (individual incentives) or a team comprised by the patient and a partner (mixed incentives).
Design: Three-month randomized control feasibility study to test the feasibility of implementing three types of intervention with economic incentives in patients with diabetes mellitus.
Setting: Diabetes outpatient clinics from a public hospital in Peru.
Detailed description
Economic incentives have been used to promote changes in habits such as smoking and weight loss. However, no studies have been done to determine the impact of this strategy on the management of type 2 diabetes mellitus (T2DM). Additionally, previous studies do not describe ways to determine the amount of an economic incentive to promote behavioral changes, e.g adherence to treatment, increased physical activity and adherence to a healthy diet. There are also questions regarding the frequency of incentives, the type of incentive (cash or other prizes), and the preferred payment method that this study will allow us to explore. Furthermore, we want to test whether a "team work approach" (mixed incentives) vs. an "individual approach" (individual incentives) can also play a role in introducing behavioral changes.
The goal of the study is to learn about the implementation process of three different interventions that use economic incentives to promote behavioral changes in patients with T2DM, and identify main barriers and facilitators tied to the implementation process of each intervention.
This feasibility study will provide key insights to inform a future larger study; specifically, we will
- Learn about the experience of participants with T2DM with economic incentives.
- Learn about the experience of the companion/team support partners of the participants with T2DM.
- Evaluate the patient's receptiveness to and comprehension of the educational materials used to promote behavioral changes.
- Evaluate the patient and the companion/team support partner's receptiveness towards the received economic incentive as a tool for promoting behavioral changes.
- Explore the companion/team support partner's activities that are most effective in helping with T2DM management of patients.
- Explore whether patients with T2DM are able to keep a daily record of their efforts to manage their diabetes.
- Evaluate the feasibility of packaging and implementing a future clinical trial that evaluates the impact of the use of economic incentives and teamwork in people with T2DM.
From a clinical perspective, we will evaluate the feasibility of reaching the proposed clinical goals in terms of weight loss and HbA1c levels after the intervention period.
Interventions
Diabetes education (all arms). In the introductory meeting, a diabetes educator will explain to the participants all the procedures, including details of the number of sessions, and the participant's received a manual with information about diabetes management with a tailored weight loss plan. Each participant will be offered up to seven follow- up sessions with the diabetes educator, every two weeks, plus a final session, thus totaling up to 9 one-to-one interactions during the trial, provided that the participant attended all of their meetings. Participants will also be provided with a logbook to register their efforts regarding introducing changes in diet and physical activity. The information from this logbook will provide the starting point for conversations with the diabetes educator during the follow-up sessions, every two weeks.
Goal setting (all arms). To determine eligibility for a cash reward, three goals were pre-specified: (1) Weight loss, 80 PEN if the participant loses one kilogram over a period of two weeks, (2) HbA1c level, 200 PEN if the participant achieves, at the end of the study, a decrease in 1% compared to their baseline level, and (3) HbA1c level and control, 400 PEN if the participant achieves, at the end of the study, a decrease ≥1% of A1c or reaches levels of A1c ≤6.5% compared to their baseline level. At the end of the study, targets for weight loss and HbA1c were evaluated independently, i.e. participants could receive more than one reward provided that each independent target was achieved.
Companion/team support (Arm 2 and Arm 3). A companion/team support for each participant also receives information about diabetes care in the initial session and a brochure to guide and support the treatment process of the participant. The activities of the companion/team support member will be recorded, and they will be offered to join the follow- up sessions with the patient, every two weeks, but these will not be compulsory.
Cash rewards. Two types of rewards will be considered. (1) Individual rewards (Arm 1 and Arm 2), the reward will be provided to the participant. If the participant were to have a companion/team support partner, the cash reward was given to the participant and no rules about sharing the reward (or not) with their companion/team support are established. (2) Shared rewards (Arm 3), i.e. the participant and their companion/team support will receive 50% of the cash reward each.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Individual incentives - Arm 1 | Experimental | Behavioral: Diabetes education, Behavioral: Goal setting, Behavioral: Individual RewardThis arm receives diabetes education + goal setting + individual rewards |
| Mixed incentives (Altruism) - Arm 2 | Experimental | Behavioral: Diabetes education, Behavioral: Goal setting, Behavioral: Companion Support, Behavioral: Individual RewardThis arm receives diabetes education + goal setting + companion support + individual rewards |
| Mixed Incentives (Cooperation) - Arm 3 | Experimental | Behavioral: Diabetes education, Behavioral: Goal setting, Behavioral: Companion Support, Behavioral: Shared RewardThis arm receives diabetes education + goal setting + companion support + shared rewards |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Type 2 diabetes mellitus
- Body mass index 25-39.9 kg/m2, irrespective of HbA1c status
- Able to give consent
- Available and committed to supporting the participant in achieving their goals
- Able to provide consent
Key exclusion criteria (6 listed)
- Diagnosis of cancer or another serious comorbidity
- Pharmacotherapy for weight loss or corticosteroids
- Pregnant women
- Blindness, amputation, foot ulcer or being on dialysis
- Be companion/team support for another participant in the trial
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Diabetes educationParticipants interact with a diabetes educator (DE), every two weeks. | Behavioural | Individual incentives - Arm 1, Mixed Incentives (Cooperation) - Arm 3, Mixed incentives (Altruism) - Arm 2 |
| Goal settingGoals for weight loss and change in levels of HbA1c | Behavioural | Individual incentives - Arm 1, Mixed Incentives (Cooperation) - Arm 3, Mixed incentives (Altruism) - Arm 2 |
| Companion SupportPatient has a companion/team support partner to support achieving goals. | Behavioural | Mixed Incentives (Cooperation) - Arm 3, Mixed incentives (Altruism) - Arm 2 |
| Individual RewardThe cash reward is given to the patient with diabetes. | Behavioural | Individual incentives - Arm 1, Mixed incentives (Altruism) - Arm 2 |
| Shared RewardPatients with diabetes and their companion support will each receive 50% of the cash reward. | Behavioural | Mixed Incentives (Cooperation) - Arm 3 |
Primary outcome
Change in Glycated Hemoglobin
Time frame: Baseline and 3 months
HbA1c change at 3 months from baseline
1 secondary outcome
Change in Weight
Time frame: Baseline and 3 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Feb 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 30066604Pesantes MA, Del Valle A, Diez-Canseco F, Bernabe-Ortiz A, Portocarrero J, Trujillo A, Cornejo P, Manrique K, Miranda JJ. Family Support and Diabetes: Patient's Experiences From a Public Hospital in Peru. Qual Health Res. 2018 Oct;28(12):1871-1882. doi: 10.1177/1049732318784906. Epub 2018 Aug 1.
- Derived from this study: PubMed 30662958Miranda JJ, Lazo-Porras M, Bernabe-Ortiz A, Pesantes MA, Diez-Canseco F, Cornejo SDP, Trujillo AJ. The effect of individual and mixed rewards on diabetes management: A feasibility randomized controlled trial. Wellcome Open Res. 2019 Feb 5;3:139. doi: 10.12688/wellcomeopenres.14824.3. eCollection 2018.
- REVISED A descriptive study of potential participant preferences for the design of an incentivised weight loss programme for people with type 2 diabetes mellitus attending a public hospital in Lima, PeruLink provided by the sponsor.
- The effect of individual and mixed rewards on diabetes management: A feasibility randomized controlled trialLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Following on MRC's data sharing policy, we plan to make our quantitative datasets available in platforms for data sharing (e.g. Figshare, etc.). Qualitative data will be available upon request.
Related trials for Diabetes Mellitus, Type 2
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jaime Miranda, MD, PhD principal investigator
Universidad Peruana Cayetano Heredia
Antonio Trujillo, PhD principal investigator
Johns Hopkins Bloomberg School of Public Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Diabetes education, Goal setting and Companion Support in people with Diabetes Mellitus, Type 2, run by Universidad Peruana Cayetano Heredia at 1 site in Peru.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Peru. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 2 Feb 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Glycated Hemoglobin (time frame: Baseline and 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02891382, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2024.